Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness

Vanda Pharmaceuticals366 enrolled

Overview

A multi-center, randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in subjects affected by motion sickness during travel

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

366

Conditions

Motion Sickness

Interventions

TradipitantDRUG

Oral Capsule

PlaceboDRUG

Oral Capsule

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * History of motion sickness * Age 18-75 Exclusion Criteria: * Nausea-inducing disorder other than motion sickness * BMI\>40 * History of intolerance and/or hypersensitivity to Neurokinin-1 Receptor antagonists

Locations (7)

Pacific Research Network, LLC

San Diego, California, United States

Santa Monica Clinical Trials

Santa Monica, California, United States

Gulfcoast Psychiatric Associates

Fort Myers, Florida, United States

Harmony Clinical Research

North Miami Beach, Florida, United States

Outcomes

Primary Outcomes

Prevention of Vomiting Measured by Vomiting Assessment (VA)

Prevention of vomiting measured by Vomiting Assessment (VA) score in tradipitant high dose. The VA is a 1-item questionnaire to objectively measure the incidence of emesis. Participants will indicate whether or not they have vomited. The Count of Participants indicates participants who vomited.

Time frame: 1 day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.